Day One Biopharmaceuticals, Inc. (DAWN) News
Filter DAWN News Items
DAWN News Results
|Loading, please wait...|
DAWN News Highlights
- For DAWN, its 30 day story count is now at 2.
- Over the past 7 days, the trend for DAWN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AVEO and STAR are the most mentioned tickers in articles about DAWN.
Latest DAWN News From Around the Web
Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncolog
JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Day One Biopharmaceuticals (DAWN - Research Report) today and set a price target of $40.00. The company's shares closed last Friday at $23.80.According to TipRanks, Roy is a 4-star analyst with an average return of 4.2% and a 32.74% success rate. Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Curis, and AVEO Pharma.Currently, the analyst consensus on Day One Biopharmaceuticals is a Strong Buy with an average price target of $36.75.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $28.70 and a one-year low of $5.44.
Day One Biopharmaceuticals, Inc. (DAWN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded development of tovorafenib with initiation of pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in pLGG Completed $172.5 million upsized public offering providing funding into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 04
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tues
The big shareholder groups in Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) have power over the company...
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 84.6% in Day One Biopharmaceuticals, Inc. (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%.
Downturns can bring a lot of pain, but they can also bring on plenty of opportunities, as lower stock prices start making costs of entry more attractive. Before taking advantage of these opportunities, however, investors need to find a recognizable signal that will set them apart. One popular signal to follow is the insider buying, the trades made by high-ranking company officers whose positions give them the ‘inside’ track on their company’s likely prospects – and therefore, of the stock’s prospects. These officers hold high positions, and they are responsible for bringing in profits for both shareholders and company Boards, and for ensuring future stock performance.
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) came into the limelight after an insider trading activity worth $18 million was conducted two days ago. Since then, shares of this $1.2-billion biopharmaceutical company have grown 1.4%. DAWN stock closed at $16.01 on Wednesday. A look at the TipRanks Insider Trading tool reveals more information on Tuesday’s corporate insider activity. According to TIpRanks, AI Day1 LLC, which owns more than 10% stake in Day One Biopharmaceuticals, bought 1.2 million shares of Day One Biopharmaceuticals for $15 per share. The insider now holds DAWN stock worth $174.1 million. In addition to this, one Uninformative Sell transaction was made six days ago.